PriceMDs today announced the launch of a new API integration platform designed to help pharmacy benefit managers (PBMs), third-party administrators (TPAs), and healthcare organizations streamline ...

The FDA has extended its review of Eisai and Biogen's new subcutaneous formulation of Alzheimer's disease therapy Leqembi – seen as the key to accelerating its sales uptake – by three months.

Merck (MRK) and Eisai (ESALF) announced on Tuesday that a late-stage trial evaluating two combination regimens involving the U.S. pharma giant's anti-PD1 inhibitor Keytruda failed to reach the main ...

Michele Randazzo has helped turn communications into a strategic force at Eisai, shaping how the company’s science, purpose and culture show up in the world. Over the past decade, she has led ...

Industry is finally back for season four, and after the cliffhanger we were all left on at the end of season three, we literally couldn't wait another day. In season four, a lot of our favorite ...

Two years after revamping its developer programs and pricing, X is expanding the closed beta of a pay-per-use plan for its API to more developers. The social network is accepting applications from ...

Patients with mild to moderate Alzheimer’s disease can now treat themselves at home with the latest drug for the neurodegenerative disease. In August, the FDA approved the first self-injectable form ...

SAN FRANCISCO--(BUSINESS WIRE)--Deepgram, the leading voice AI platform for enterprise use cases, today announced the general availability (GA) of its Voice Agent API, a single, unified voice-to-voice ...